Top Markets
Coin of the day
Andros Pharmaceuticals Co.,Ltd Andros Pharmaceuticals Co.,Ltd

Andros Pharmaceuticals Co.,Ltd

6917
Rangering i aksjer #24797
Andros Pharmaceuticals Co., Ltd. operates as a biopharmaceutical enterprise,... Andros Pharmaceuticals Co., Ltd. operates as a biopharmaceutical enterprise, concentrating on the advancement of novel drug delivery platform technologies. Its development pipeline features APC101, a metered-dose, quick-drying, film-forming spray undergoing Phase IIa clinical investigation for the management of pain linked to post-herpetic neuralgia. Also in development is APC201, an innovative topical anesthetic formulation currently in Phase I/II trials for Osteoarthritis treatment, alongside an siRNA (small interfering RNA) compound functioning as an antisense oligonucleotide and DNA candidate. In the preclinical phase, the company is advancing APC310 and APC501, both intended as anesthetics for intravenous catheter insertion and venipuncture. Another preclinical asset, APC401, is a specialized emulsified solution targeting post-surgical pain relief. Beyond its developmental programs, Andros Pharmaceuticals also provides LALP cream for dermal analgesic use, iMinos solution for treating Alopecia Androgenetica, and T4 endonuclease V. Established in 2008, the firm maintains its headquarters in Zhubei, Taiwan.
Aksjekurs
$1.03
Markedsverdi
$56.61M
Endring (1 dag)
0.00%
Endring (1 år)
80.30%
Land
TW
Handel Andros Pharmaceuticals Co.,Ltd (6917)

Kategori

Utbyttehistorikk for Andros Pharmaceuticals Co.,Ltd (6917)
Andros Pharmaceuticals Co.,Ltd (aksjesymbol: 6917) har gitt totalt 0 utbyttebetalinger.
Summen av alle utbytter (justert for aksjesplitt): 0.00
Utbytteavkastning (TTM): 0
Utbyttebetalinger for Andros Pharmaceuticals Co.,Ltd (6917) fra 2026 til 2026
Årlige utbyttebetalinger
År Utbytte (justert for aksjesplitt) Endre
Ikke nok data for de angitte datoene.
Liste over alle utbyttebetalinger
År Utbytte Endre
Ikke nok data for de angitte datoene.
Utbyttebetalinger for lignende selskaper eller konkurrenter
Selskap Antall utbyttebetalinger Land
0.00%
US
0.00%
NL
0.00%
US
64.00%
AU
0.00%
CH